Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
about
The Utility of Molecular Imaging in Prostate CancerPSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical StatusProstate-specific membrane antigen as a target for cancer imaging and therapyPET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesTarget Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingCorrelation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapseProstate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL.Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia.Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.Prostate Cancer Imaging with Novel PET Tracers.Current use of PSMA-PET in prostate cancer management.New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.A urologist's perspective on prostate cancer imaging: past, present, and future.PET imaging of recurrent and metastatic prostate cancer with novel tracers.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseStatus and trends in the development of clinical diagnostic agents.PSMA PET and Radionuclide Therapy in Prostate Cancer.The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.Metal-Based PSMA Radioligands.Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTBiphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.Developments in oncological positron emission tomography/computed tomography assessment.PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions.Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.
P2860
Q26764746-92B7D196-5E69-4379-830F-AEFBA5B309FBQ26774920-B5A98AAF-FCC3-4C2E-B28D-A903E706C8B1Q26799439-29A2F1BD-D5CC-49F9-9FBD-7D6A982DB8D3Q28067404-559DE3DC-60EB-475C-9B45-195AD0D85AE5Q28074669-C7BFFEBE-81E9-4B5F-8E70-56EF102960E4Q31137270-12C64E0B-5162-4878-861E-B3BCE4248391Q31145236-89F1C6A0-46DD-414C-B3FD-DBE1E3D08CDDQ33668676-46454ED7-12A8-4667-9201-9B898728BFA9Q33914844-03B64921-4FF4-4D98-9144-A978EC53B46DQ33917903-04300EDC-69CA-4757-B961-F29BB6E668C7Q36166095-1F1689D7-B275-406D-B2E2-9741C69BAF01Q37390674-80CB2038-370D-48FC-B311-561148C91116Q37594922-2CCFE695-3D50-45FA-81C3-18368117810DQ37662752-0B73BD0D-1079-4D8E-A0CB-56409556F3B4Q38638455-B136688B-52DF-45AC-85D3-2A5CC65CAC80Q38639486-BD72F254-66E3-4677-8F53-BE2C41FB2CC8Q38648799-9D94D8AD-C378-4193-AA5D-3FD043D04989Q38665724-23EE271E-DA40-4E1F-B42C-A75996821830Q38732369-20FF315E-2D96-4525-B10B-21F65FC59E01Q38744524-114CEBA5-E581-45C0-BF15-35A5B6599775Q38757513-76CE94DE-2FA9-4113-BB91-B5010BB71E03Q38762963-A89E08FE-EAAC-44C7-A8B6-76848F7CD912Q38766194-405580EA-6676-4919-8D60-6FAB7D5D52A7Q38784721-305A2FDD-C4F3-4759-AFDB-8DDE1F5184FEQ38823661-36DA56E5-E1C0-44C2-9996-1F1E78C11D28Q38831029-83393464-4786-40C2-89CC-68DD71A9E456Q38831232-02222F0B-98E5-4C4F-9563-596A1455D080Q38995734-06EF9275-45EB-4243-BCB0-A32EDA4694E6Q39003089-210EC23A-53D8-4D85-82FB-120007BCDA07Q39143896-EB7B2312-1F23-4A84-9BAD-A23961296478Q39198527-78C6556C-EE6D-431E-B10D-00B7D38B0812Q39307896-34F500BF-133C-416F-8941-4B8D00474118Q39797249-054BE133-BB6B-4A6F-8CB4-73454E5068E5Q39869574-20407F45-3EF1-4155-8B51-055C9338D24DQ39922053-B105DD28-4C5B-4B82-9663-21E933F874D3Q40327142-0F7F0398-32D1-4524-B6A6-7E3E7E3EB664Q41965876-A9C3AC37-B9EA-4B55-B834-BAFC58E009D7Q42328242-26E514E5-6D00-4498-B65E-80867A1B57ECQ43119026-B806CD50-D3F0-489D-A84E-80B3B4E5F02CQ45753373-D13EF3D1-A175-4666-A014-25B815C73FB2
P2860
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparison of [(18)F]DCFPyL an ...... with Relapsed Prostate Cancer.
@en
type
label
Comparison of [(18)F]DCFPyL an ...... with Relapsed Prostate Cancer.
@en
prefLabel
Comparison of [(18)F]DCFPyL an ...... with Relapsed Prostate Cancer.
@en
P2093
P2860
P1476
Comparison of [(18)F]DCFPyL an ...... with Relapsed Prostate Cancer.
@en
P2093
Boris D Zlatopolskiy
Carsten Kobe
Felix Dietlein
Georg Kuhnert
Klaus Schomäcker
Markus Dietlein
Matthias Schmidt
Philipp Krapf
Raphael Richarz
Simone Stockter
P2860
P2888
P304
P356
10.1007/S11307-015-0866-0
P577
2015-08-01T00:00:00Z
P5875
P6179
1006839268